The Overview of Lung Cancer Screening
Abstract
Lung cancer is a common cause of death among all cancers and its incidence has increased. Because it is related to smoking, which trend currently increases in the young population. Moreover, patiens with lung cancer in the early stages usually have no symptom. Lung cancer screening is therefore important to increase the chance of detecting lung cancer in the early stage. Effective early treatment increases survival rate. The first, lung cancer screening is chest x-ray with sputum cytology and nowadays use of low dose CT chest for screening lung cancer can increase detection rates of lung cancer. However, more pathologic findings are detected in low dose CT chest which leads to more treatment processes, increasing costs. There may be more complications. Indication determination to select high risk population is important to increase efficiency in screening.
Keywords : Lung cancer screening, Low dose CT chest, Artificial Intelligence
References
Zheng M. Classificationand pathology of lung cancer. Surg Oncol Clin N Am 2016;25:447-68.
American cancer society. Lung cancer early detection, diagnosis, and staging. Cancer.org 1.800.227.2345
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Ca Cancer J Clin 2022;72:7-33.
สถาบันมะเร็งแห่งชาติ กรมการแพทย์ กระทรวงสาธารณสุข. ทะเบียนมะเร็งระดับโรงพยาบาล พ.ศ. 2564. กรุงเทพฯ: กลุ่มงานดิจิทัลการแพทย์ สถาบันมะเร็งแห่งชาติ; 2565.
Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years observations on male British doctors. BMJ 2004;328:1519.
Boffetta P. Involuntary smoking and lung cancer. Scand J Work Environ Health 2002;28(2):30-40.
Fontana RS, Sanderson DR, Miller WE, Woolner LB, Taylor WF, Muhm JR. The Mayo Lung Project: preliminary report of “early cancer detection” phase. Cancer 1972;30:1373-80.
Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000;92(16):1308-16.
Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, et al. Lung cancer screening in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. J Natl Cancer Inst 2010;102(10):722-31.
Frost JK, Ball WC Jr, Levin ML, Tockman MS, Baker RR, Carter D, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytology screening in the John Hopkins study. Am Rev Respir Dis 1984;130(4):549-54.
Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer results of the Memorial Sloan-Kettering study in New York. Chest 1984;86(1):44-53.
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248(1):254-63.
Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, et al. Peripheral lung Cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201(3):798-802.
National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology 2011;258(1):243-53.
National lung screening trial research team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368(21):1980-91.
Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330-8.
Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J RespirCrit Care Med 2015;191(10):1166-75.
Wille MMW, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016;193(5):542-51.
Paci E, Puliti D, Pegna AL, Carrozzi L, Picozzi G, Falaschi F, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017;72(9):825-31.
Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30(7):1162-69.
Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2020;146(6):1503-13.
Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382(6):503-13.
Sadate A, Occean BV, Beregi JP, Hamard H, Addala T, de Forges H, et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. European Journal of Cancer 2020;134:107-14.
Lam DCL, Liam CK, Andarini S, Park S, Tan DSW, Singh N, et al. Lung cancer screening in Asia: an expert consensus report. Journal of Thoracic Oncology 2023;18:1303-22.
Yang P. National lung cancer screening program in Taiwan: the TALENT study. Journal of Thoracic Oncology 2021;16:S58-62.
Lee J, Kim Y, Kim HY, Goo JM, Lim J, Lee CT, et al. Feasibility of implementing a national lung cancer screening program: interim results from the Korean lung cancer screening project (K-LUCAS). Transl Lung Cancer Res 2021;10(2):723-36.
พิธาน โฆษิตชัยวัฒน์. เภสัชเศรษฐศาสตร์. คณะเภสัชศาสตร์ มหาวิทยาลัยสยาม 2560: 1-10.
Criss SD, Cao P, Bastini M, Haaf KT, Chen Y, Sheehan DF, et al. Cost-effectiveness analysis of lung cancer screening in the United States. Ann Intern Med 2019;171:796-804.
Kowada A. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modeling study. BMC Pulmonary Medicine 2022;22:19.
Griffin E, Hyde C, Long L, Campbell JV, Coelho H, Robinson S, et al. PCN 248 Lung cancer screening by low dose computerized tomography: a cost effectiveness analysis of alternative programs in the united kingdom using a newly developed natural history based economic model. Value in Health 2020;23:s66.
Tomonaga Y, Haff KT, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, et al. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-a modelling study. Lung Cancer 2018;121:61-9.
Sim Y, Chung MJ, Kotter E, Yune S, Kim M, Do S, et al. Deep convolutional neural network-based software improves radiologist detection of malignant lung nodules on chest radiographs. Radiology 2020;294(1):199-209.
Nasrullah N, Sang J, Alam MS, Mateen M, Cai B, Hu H. Automated lung nodule detection and classification using deep learning combined with multiple strategies. Sensors (Basel) 2019;19(17):3722.
Thong LT, Chou HS, Chew HSJ, Lau Y. Diagnostic test accuracy of artificial intelligence-based imaging for lung cancer screening: a systematic review and meta-analysis. Lung Cancer 2023;176:4-13.
Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. British Journal of Cancer 2008;98:1602-7.
Zhang T, Chen X, Li C, Wen X, Lin T, Huang J, et al. Cost-effectiveness analysis of risk factor-based lung cancer screening program by low-dose computer tomography in current smokers in China. Cancers(Basel) 2023;15(18):4445
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี